Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Up 6.6% – Time to Buy?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)’s stock price traded up 6.6% during mid-day trading on Tuesday . The stock traded as high as $26.09 and last traded at $25.81. Approximately 60,826 shares traded hands during trading, a decline of 83% from the average daily volume of 362,893 shares. The stock had previously closed at $24.21.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DMRA. Royal Bank Of Canada initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. HC Wainwright started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They set a “buy” rating and a $45.00 price target for the company. Wedbush reissued an “outperform” rating and set a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. Finally, Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Damora Therapeutics, Inc. Common Stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Up 4.2%

The company’s fifty day moving average price is $23.73 and its 200-day moving average price is $25.46. The stock has a market capitalization of $1.67 billion, a PE ratio of -4.85 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.23). Equities research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $40,000. Geode Capital Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $266,000. Virtu Financial LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $49,000. Sigma Planning Corp purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $334,000. Finally, Two Sigma Investments LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $76,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.